Asthma Clinical Trial
Official title:
Optimizing Discharge After Emergency Department Visits for Children With Uncontrolled Asthma
Verified date | April 2018 |
Source | Rhode Island Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Many children have asthma and this causes problems with their health. A lot of children with
uncontrolled asthma use emergency departments for asthma care, and so this is an ideal place
for an intervention for these children. One intervention is prescribing inhaled steroids to
children with uncontrolled asthma, but currently this is rarely done in the emergency
department. Inhaled steroids have been shown to be good at making children better long-term
when they have uncontrolled asthma.
This study identifies children in the emergency department with uncontrolled asthma using a
tool called the Pediatric Asthma Control and Communication Instrument (PACCI). If children
meet criteria for uncontrolled asthma they will be randomly assigned to either: 1) routine
asthma care which includes close follow up with their doctor or 2) prescribing of an inhaled
corticosteroid from the emergency department. The investigators hypothesize that children who
are prescribed inhaled steroids for uncontrolled asthma from the emergency department will
have better 6 month asthma control than children who receive routine asthma care.
Status | Terminated |
Enrollment | 118 |
Est. completion date | April 2018 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years to 12 Years |
Eligibility |
Inclusion Criteria: - 3 - 12 years of age - child has asthma diagnosed by a doctor based on parental/caregiver report - child is not already properly using an ICS or being discharged with an ICS Exclusion Criteria: - The child has previously participated in this study - The child has major co-morbid disease of the heart or lungs (examples include cystic fibrosis, heart disease, muscular dystrophy and cerebral palsy with immobility. It does not include allergic rhinitis or a history of respiratory infections such as pneumonia or bronchiolitis. - The child's parents/caregivers do not speak English - The child is not going to be discharged from the emergency department (e.g. hospitalization) |
Country | Name | City | State |
---|---|---|---|
United States | Rhode Island Hospital / Hasbro Children's Hospital | Providence | Rhode Island |
Lead Sponsor | Collaborator |
---|---|
Rhode Island Hospital | American Lung Association |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quality-of-life Using the Integrated Therapeutics Group Child Asthma Short Form | The Integrated Therapeutics Group Child Asthma Short Form (ITG-CASF) has been validated in the ED setting for children 2 to 17 years old, is reliable (Cronbach's a =0.70), and can be administered by telephone. Each item is rated on a 5-point scale. Each response is scaled as a percentage of the maximum response, and the total score is the maximum percentage based on the number of questions answered. The scores range from 0 (minimum) - 100 (maximum), with higher scores reflecting better quality of life. The change in ITG-CASF scores for children with improved overall clinical status are 10 points higher than when children have not improved. | 6 months | |
Secondary | ED Visits for Asthma | Emergency department visits for asthma over a 6 month period by parent report. | 6 months | |
Secondary | Primary Care Visits for Well Checks | Primary care visits well checks over a 6 month period by parent report. | 6 months | |
Secondary | Hospitalizations for Asthma | Hospitalizations for asthma over a 6 month period by parent report. | 6 months | |
Secondary | Unscheduled Primary Care Visits | Unscheduled primary care visits for asthma over a 6 month period by parent report. | 6 months | |
Secondary | Oral Steroid Courses | Oral steroid courses over a 6 month period by parent report. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|